Please ensure Javascript is enabled for purposes of website accessibility

Why Okta Stock Is Rising Today

By Chris Neiger - Updated Apr 13, 2021 at 2:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors believe a pause on one coronavirus vaccine could slow the pace of America's reopening economy.

What happened

Shares of Okta (OKTA 6.86%) were climbing today after health officials in the U.S. recommended that use of the Johnson & Johnson coronavirus vaccine be paused until more information about potential blood clots can be assessed. 

The tech stock was up 6% as of 1:57 p.m. EDT.

So what 

Both the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention recommended that the Johnson & Johnson vaccine not be used right now "out of an abundance of caution." The agencies are reviewing "six reported U.S. cases of a rare and severe type of blood clot" that occurred in those individuals after taking the vaccine. To date, 6.8 million doses of the Johnson & Johnson vaccine have been administered.

Red and green line graphs on a dark background.

Image source: Getty Images.

So why would Okta's stock rise on this news? Because some investors are thinking that if there are fewer vaccines being distributed in the U.S. it could slow down the pace of companies bringing their employees back into the office. And if that happens, then the services offered by some tech companies, like Okta, will continue to be in high demand. 

Okta offers identity and access management (IAM) services that help companies manage logins and data access for customers and employees. 

Now what 

Okta's share price has been a bit volatile since the beginning of this year, as investors try to adjust their investment strategies based on whether or not they think the U.S. economy is opening back up. This could likely cause more instability from tech stocks in the coming months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Okta Stock Quote
Okta
OKTA
$102.56 (6.86%) $6.58
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.14 (-0.77%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.